On Oct. 10, 2025, AstraZeneca announced a historic agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation.

As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the Company’s recently announced $50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.

AstraZeneca’s commitment to the US and American patients is further reflected in the Company’s largest single investment in a manufacturing facility to date, where the Company broke ground in Virginia. This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline.

Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.